Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Initial search results include only NCI-sponsored clinical trials. To search all trials, click the "REFINE SEARCH" button, scroll down to the Trial ID/Sponsor section and select the "All" check box in the Sponsor of Trial section.

View Content for:
Display:
?
Drug:  exatecan mesylate
Find trials that include:  Any drugs shown
Trial Status:  Closed
Results 1-17 of 17 for your search:
Start Over
Gemcitabine With or Without Exatecan Mesylate in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer
Phase: Phase III
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CDR0000068880, DAIICHI-8951A-PRT031, MSKCC-02011, NCT00023972
Phase II Study of DX-8951f in Patients with Fluorouracil-Resistant Advanced or Metastatic Adenocarinoma of the Colon or Rectum (Summary Last Modified 12/1999)
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI, Pharmaceutical / Industry
Protocol IDs: DAIICHI-8951A-PRT007, MSKCC-98103, NCI-G99-1505
Chemotherapy in Treating Patients With Prostate Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CDR0000067146, DAIICHI-8951A-PRT012, SACI-IDD-99-03, SLLH-BHS-99-0020, NCT00004045
DX-8951f in Treating Patients With Metastatic Cancer of the Pancreas
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CDR0000067147, DAIICHI-8951A-PRT009, JHOC-99062405, MSKCC-99014, NCT00003951
Chemotherapy in Treating Women With Metastatic Breast Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CDR0000067148, DAIICHI-8951A-PRT011, MDA-ID-98308, NCT00004046
Chemotherapy in Treating Patients With Recurrent, Metastatic, or Unresectable Ovarian, Fallopian Tube, or Peritoneal Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CDR0000067258, DAIICHI-8951A-PRT008, MDA-DM-98265, NCT00004060
DX-8951f in Treating Patients With Liver Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 16 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CDR0000067329, DAIICHI-8951A-PRT016, MDA-ID-99145, MSKCC-99058, UCHSC-00891, NCT00004108
DX-8951f in Treating Women Who Have Advanced or Recurrent Cancer of the Cervix
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CDR0000067525, DAIICHI-8951A-PRT015, MDA-DM-99247, NCT00004866
DX-8951f in Treating Patients With Biliary Cancer
Phase: Phase II
Type: Treatment
Status: Completed
Age: 16 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CDR0000067736, DAIICHI-8951A-PRT020, MDA-ID-99379, MSKCC-99110, SACI-IDD-99-31, UCHSC-00892, UTHSC-9905011256, NCT00005938
DX-8951f in Treating Patients With Metastatic Stomach Cancer
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CDR0000068663, DAIICHI-8951A-PRT028, SACI-IDD-00-27, UTHSC-0015011134, NCT00017212
Exatecan Mesylate in Treating Patients With Advanced Soft Tissue Sarcoma
Phase: Phase II
Type: Treatment
Status: Completed
Age: 15 to 75
Sponsor: Other
Protocol IDs: EORTC-62006, NCT00041236
Exatecan Mesylate in Treating Children With Relapsed or Refractory Rhabdomyosarcoma
Phase: Phase II
Type: Treatment
Status: Completed
Age: Any age
Sponsor: Pharmaceutical / Industry
Protocol IDs: CDR0000271888, DAIICHI-8951A-PRT033, SJCRH-DXRMS, NCT00055939
Exatecan Mesylate in Treating Patients With Ewing's Sarcoma, Primitive Neuroectodermal Tumor, or Desmoplastic Small Round Cell Tumor
Phase: Phase II
Type: Treatment
Status: Completed
Age: Any age
Sponsor: Pharmaceutical / Industry
Protocol IDs: CDR0000271889, DAIICHI-8951A-PRT034, SJCRH-DXEWS, NCT00055952
Chemotherapy in Treating Patients Who Have Hematologic Cancer
Phase: Phase I
Type: Treatment
Status: Completed
Age: Not specified
Sponsor: Pharmaceutical / Industry
Protocol IDs: CDR0000067149, DAIICHI-8951A-PRT014, MDA-ID-99013, NCI-V99-1556, NCT00004047
DX-8951f in Treating Children With Advanced Solid Tumors or Lymphomas
Phase: Phase I
Type: Treatment
Status: Completed
Age: 21 and under at diagnosis
Sponsor: Pharmaceutical / Industry
Protocol IDs: CDR0000067330, DAIICHI-8951A-PRT013, MSKCC-99071, UTHSC-9895011445, NCI-V99-1573, NCT00004212
Start Over